s 16020-2 has been researched along with 9-hydroxyellipticine in 1 studies
| Studies (s 16020-2) | Trials (s 16020-2) | Recent Studies (post-2010) (s 16020-2) | Studies (9-hydroxyellipticine) | Trials (9-hydroxyellipticine) | Recent Studies (post-2010) (9-hydroxyellipticine) |
|---|---|---|---|---|---|
| 20 | 2 | 1 | 76 | 0 | 4 |
| Protein | Taxonomy | s 16020-2 (IC50) | 9-hydroxyellipticine (IC50) |
|---|---|---|---|
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.205 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.6 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaminade, F; Delaporte, C; Jacquemin-Sablon, A; Le Mée, S; Markovits, J; Saucier, JM | 1 |
1 other study(ies) available for s 16020-2 and 9-hydroxyellipticine
| Article | Year |
|---|---|
Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinogenicity Tests; Cloning, Molecular; Cricetinae; DNA; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ellipticines; Sequence Analysis, DNA; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |